NCT04327232 is a Phase 2 clinical trial of Spironolactone 25mg in Atrial Fibrillation, sponsored by National University Hospital, Singapore.

Who is sponsoring NCT04327232?

NCT04327232 is sponsored by National University Hospital, Singapore.

What drugs are being tested in NCT04327232?

Interventions in NCT04327232: Spironolactone 25mg, Placebo oral tablet.

What condition does NCT04327232 study?

NCT04327232 studies Atrial Fibrillation.

Is NCT04327232 still recruiting?

NCT04327232 is currently status unknown. Last updated 31 March 2020.

Last reviewed 2020-03-31 · How we verify

NCT04327232

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

Status unknown Phase 2 Last updated 31 March 2020

What this trial tests

Phase 2 trial testing Spironolactone 25mg in Atrial Fibrillation in 184 participants. Status unknown.

Timeline

23 May 2018

Primary endpoint
31 May 2022

31 May 2022

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	184
Start date	23 May 2018
Primary completion	31 May 2022
Estimated completion	31 May 2022
Sites	4 locations across Singapore

Drugs / interventions tested

Spironolactone 25mg — full drug profile →
Placebo oral tablet — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

National University Hospital, Singapore

Who can join

Adults 21 to 100, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This proposal details the implementation of an international (Singapore and New Zealand) multi-centre study to test a novel therapeutic strategy aimed at reducing the burden of atrial fibrillation - an important medical condition with major healthcare implications. Unique aspects of this study include i) a non-arrhythmic treatment target (mineralocorticoid receptor antagonism) -targeting the arrhythmogenic substrate of AF before it becomes permanently established, ii) the use of pacemaker monitoring capability to accurately document AF burden, thus increasing the power of the study and iii) multi-national collaborative, double blind design.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other National University Hospital, Singapore trials

Trials by the same sponsor.

NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04327232 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
Last refreshed: 31 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04327232.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing